Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699810 · ClinicalTrials.gov registry record · Phase 4
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
A Phase 4 study of Ketosis Prone Diabetes, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT06699810: Recruiting Phase 4 study of Ketosis Prone Diabetes, sponsored by Emory University.
NCT06699810 is a Phase 4 study of Ketosis Prone Diabetes that is actively recruiting participants, run by Emory University. The registered enrollment target is 12 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06699810, a Phase 4 study of Ketosis Prone Diabetes, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
Primary Outcome
The day-to-day changes in blood glucose in KPDM will be quantified using CGMs.
Conditions Studied
Interventions
- DRUG Insulin
- DEVICE Continuous Glucose Monitoring
Study Locations (2)
Georgia
- Grady Health System - Atlanta
- Emory University Hospital Midtown - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What NCT06699810 shows while recruiting
NCT06699810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Ketosis Prone Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Insulin is the first listed.
NCT06699810 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06699810 about?
NCT06699810 is a clinical study titled "Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity". The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
What is the current status of trial NCT06699810?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2025-01-23. Estimated completion is 2025-12.
What conditions does trial NCT06699810 study?
This clinical trial studies the following conditions: Ketosis Prone Diabetes.
What interventions are being tested in trial NCT06699810?
The interventions under investigation include: Insulin (DRUG), Continuous Glucose Monitoring (DEVICE).
Who is sponsoring clinical trial NCT06699810?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699810 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ketosis Prone Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06699810's enrollment target sits among peer trials
12 1914th of 2000 higher than 70 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI